Statistically significant improvements in lung function, symptoms and quality of life
36% reduction in rate of exacerbations over 24 weeks
Well tolerated safety profile over 48 weeks
NDA submission planned for 1H 2023
Conference call today at 8:30 a.m. EST / 1:30 p.m. GMT
LONDON and RALEIGH, N.C., Dec. 20, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), today announces positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). The ENHANCE-1 trial successfully met its primary and key secondary endpoints demonstrating significant improvements in lung function, symptoms and quality of life measures. In addition, ensifentrine substantially reduced the rate and risk of COPD exacerbations. Ensifentrine was well tolerated over 24 and 48 weeks.